Therapeutic effects of TACI-Ig on rats with adjuvant-induced arthritis via attenuating inflammatory responses - PubMed (original) (raw)
doi: 10.1093/rheumatology/keq404. Epub 2010 Dec 23.
Yujing Wu, Di Wang, Wei Wei, Qiong Qin, Guoxiong Xie, Lingling Zhang, Shangxue Yan, Jingyu Chen, Qingtong Wang, Huaxun Wu, Feng Xiao, Wuyi Sun, Juan Jin, Wenxiang Wang
Affiliations
- PMID: 21186171
- DOI: 10.1093/rheumatology/keq404
Therapeutic effects of TACI-Ig on rats with adjuvant-induced arthritis via attenuating inflammatory responses
Yan Chang et al. Rheumatology (Oxford). 2011 May.
Abstract
Objective: To investigate the effects of TACI-Ig, a recombinant fusion protein that modulates B- and T-cell activation by binding and neutralizing B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), in an established adjuvant-induced arthritis (AA) rat model.
Methods: Rats with experimental arthritis were randomly separated into different groups and then treated with TACI-Ig (0.7, 2.1, 6.3 mg/kg), rhTNFR-Fc (2.8 mg/kg), MTX (0.5 mg/kg) or IgG-Fc (6.3 mg/kg), from Day 16 to Day 34 after immunization. Arthritis was evaluated by hind paw swelling, polyarthritis index and histopathological examination. Activities of BLyS, APRIL, IL-1β, IL-2, IL-10, TGF-β1, PGE(2), TNF-α, IFN-γ, immunoglobulin (Ig)G1, IgG2a, IgM and IgA were assessed by ELISA. Cluster of differentiation (CD)20 expression was detected by immunohistochemical analysis.
Results: TACI-Ig (2.1, 6.3 mg/kg) treatment significantly reduced the severity of established arthritis using the methods of clinical observation and histopathological examination. TACI-Ig treatment inhibited expression of IgM, decreased the expression of BLyS and APRIL and regulated the balance of pro-inflammatory and anti-inflammatory cytokines in serum of AA rats. Immunohistochemical analysis demonstrated that CD20 production was reduced in spleen.
Conclusions: Data presented here demonstrate that administration of TACI-Ig significantly attenuates progression of experimental arthritis, with reductions in inflammatory response and bone and joint destruction.
Similar articles
- Therapeutic effects of TACI-Ig on rat with adjuvant arthritis.
Wang D, Chang Y, Wu Y, Zhang L, Yan S, Xie G, Qin Q, Jin J, Wang W, Fang J, Wei W. Wang D, et al. Clin Exp Immunol. 2011 Feb;163(2):225-34. doi: 10.1111/j.1365-2249.2010.04293.x. Epub 2010 Dec 13. Clin Exp Immunol. 2011. PMID: 21155990 Free PMC article. - TACI-Ig induces immune balance of Th cells in MLN via BLyS/APRIL-receptors signaling in rats with adjuvant-induced arthritis.
Qin Q, Chang Y, Wang D, Wu Y, Zhang LL, Wei W. Qin Q, et al. Int Immunopharmacol. 2011 Dec;11(12):2167-75. doi: 10.1016/j.intimp.2011.09.014. Epub 2011 Oct 11. Int Immunopharmacol. 2011. PMID: 21996540 - Therapeutic effects of TACI-Ig on collagen-induced arthritis by regulating T and B lymphocytes function in DBA/1 mice.
Liu Y, Zhang L, Wu Y, Tong T, Zhao W, Li P, Huang M, Wang W, Fang J, Wei W. Liu Y, et al. Eur J Pharmacol. 2011 Mar 11;654(3):304-14. doi: 10.1016/j.ejphar.2011.01.002. Epub 2011 Jan 16. Eur J Pharmacol. 2011. PMID: 21244850 - Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y. Shi F, et al. Immunopharmacol Immunotoxicol. 2021 Dec;43(6):666-673. doi: 10.1080/08923973.2021.1973493. Epub 2021 Sep 14. Immunopharmacol Immunotoxicol. 2021. PMID: 34519594 Review. - [Progress in the study of BLyS and APRIL on regulating T cell responses in rheumatoid arthritis].
Chang Y, Wei W. Chang Y, et al. Yao Xue Xue Bao. 2013 Jul;48(7):979-85. Yao Xue Xue Bao. 2013. PMID: 24133964 Review. Chinese.
Cited by
- CP-25, a novel compound, protects against autoimmune arthritis by modulating immune mediators of inflammation and bone damage.
Chang Y, Jia X, Wei F, Wang C, Sun X, Xu S, Yang X, Zhao Y, Chen J, Wu H, Zhang L, Wei W. Chang Y, et al. Sci Rep. 2016 May 17;6:26239. doi: 10.1038/srep26239. Sci Rep. 2016. PMID: 27184722 Free PMC article. - Emerging immunotherapies for rheumatoid arthritis.
Reynolds G, Cooles FA, Isaacs JD, Hilkens CM. Reynolds G, et al. Hum Vaccin Immunother. 2014;10(4):822-37. doi: 10.4161/hv.27910. Epub 2014 Feb 17. Hum Vaccin Immunother. 2014. PMID: 24535556 Free PMC article. Review. - Ginsenoside metabolite compound k alleviates adjuvant-induced arthritis by suppressing T cell activation.
Chen J, Wu H, Wang Q, Chang Y, Liu K, Song S, Yuan P, Fu J, Sun W, Huang Q, Liu L, Wu Y, Zhang Y, Zhou A, Wei W. Chen J, et al. Inflammation. 2014 Oct;37(5):1608-15. doi: 10.1007/s10753-014-9887-0. Inflammation. 2014. PMID: 24736881 - Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis.
Chen X, Zhao Q, Hou Y, Jiang J, Zhong W, Wang W, Yao X, Li L, Fang J, Zhang F, Hu P. Chen X, et al. Br J Clin Pharmacol. 2016 Jul;82(1):41-52. doi: 10.1111/bcp.12908. Epub 2016 Apr 7. Br J Clin Pharmacol. 2016. PMID: 26917504 Free PMC article. Clinical Trial. - β2-adrenoceptor signaling reduction in dendritic cells is involved in the inflammatory response in adjuvant-induced arthritic rats.
Wu H, Chen J, Song S, Yuan P, Liu L, Zhang Y, Zhou A, Chang Y, Zhang L, Wei W. Wu H, et al. Sci Rep. 2016 Apr 15;6:24548. doi: 10.1038/srep24548. Sci Rep. 2016. PMID: 27079168 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous